Sigachi Industries Limited — Updates, 29-11-2024: Press Release

Sigachi Industries Limited has successfully submitted a Certificate of Suitability (CEP) filing for Propafenone Hydrochloride through its subsidiary, Trimax Biosciences Pvt Ltd. This milestone is crucial for accessing the European market as it aligns with regulatory standards for product quality and safety. Propafenone is in high demand for treating cardiac arrhythmias, representing a global market currently at USD 1.2 billion, projected to grow to USD 2.1 billion by 2032, reflecting a CAGR of 7%. This growth is attributed to the rising prevalence of cardiovascular diseases and increasing healthcare expenditure.

The achievement emphasizes Sigachi’s commitment to innovation and quality in the pharmaceutical supply chain, enhancing its revenue channels and strategic positioning in highly regulated markets. As stated by MD and CEO Amit Raj Sinha, this development underscores the company’s dedication to providing reliable pharmaceutical solutions globally. Investors should view this as a positive signal for growth potential in the company.